Clarivate

MARCH 8, 2023

In recent years, there has been an increased focus on real world evidence to advance medical science and improve patient quality of life. Data lags can extend the duration of diagnostic studies substantially, ultimately delaying patient access to life-saving medications.

Patients 59

Patients Biopharma Medical science Electronics 59

Impetus Digital

AUGUST 12, 2022

Kaitlin Anstett , Senior Medical Advisor at Theratechnologies , will sit down with Natalie Yeadon , Co-founder & CEO of Impetus Digital , to share her unique insights into the way Medical Affairs teams are changing the way they are engaging and interacting with their most important stakeholders in the “new normal.” Sign up now!

Medical 52

Medical Professional Services Medical science Healthcare Provider 52

PM360

DECEMBER 20, 2024

When the first biosimilars were approved by the FDA almost a decade ago, they were expected to provide a cost-effective alternative to expensive biologics, improve accessibility for patients and reduce healthcare spending by creating competition in the biologic market. Overall, the findings of the analysis were positive.

Physicians 52

Physicians Marketing Competition Management 52

Medgadget

MARCH 2, 2023

The first human trial done in Israel proved very successful (2017-2018, finalized during COVID), and published in the Red Journal , the official journal of the American Society for Radiation Oncology), involving many patients whose cancer recurred after treatment or whose options were exhausted. which are currently recruiting patients.

Manufacturing 82

Manufacturing Leads Patients Medicine 82

European Pharmaceutical Review

MAY 23, 2024

In this Q&A, Dr Imran Khan, PhD, Vice President Medical Affairs, Hematology at Johnson & Johnson Innovative Medicine, highlights the current landscape of CAR T therapies such as CARVYKTI and touches on the future direction of the sector. 2 With this new indication, more patients will be able to access this innovative treatment.

Food and Drug Administration 110

Food and Drug Administration Food Medical Medicine 110

European Pharmaceutical Review

AUGUST 15, 2024

for patients with del(17p)/ TP53 mutation) and a favourable safety profile, including cardiac events, compared to ibrutinib ( ALPINE study ). It can be challenging to enrol patients given that, in areas of rapid advances in treatment like CLL, there are so many ongoing trials of new therapeutic approaches. for all-comers; HR=0.52

Safety 52

Safety Patients Medical Medicine 52

Pharmaceutical Technology

NOVEMBER 3, 2022

According to some estimates, between 2017 and 2047, the number of individuals living with stroke will increase by 27% in the EU. These] are life-saving medications. And patients can die when we do not have these readily available,” he says. Here, the long-term shortages can be attributed to two factors, says Page.

Medicine 111

Medicine Manufacturing Pharmacology Healthcare 111